首页> 外文OA文献 >Effects of CYP3A4 Inhibitors Ketoconazole and Verapamil and the CYP3A4 Inducer Rifampicin on the Pharmacokinetic Parameters of Fostamatinib: Results from In Vitro and Phase I Clinical Studies

【2h】

Effects of CYP3A4 Inhibitors Ketoconazole and Verapamil and the CYP3A4 Inducer Rifampicin on the Pharmacokinetic Parameters of Fostamatinib: Results from In Vitro and Phase I Clinical Studies

机译：CYP3A4抑制剂酮康唑和维拉帕米以及CYP3A4诱导剂利福平对Fostamatinib药代动力学参数的影响：体外和I期临床研究的结果

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Paul Martin; Michael Gillen; David Millson; Stuart Oliver; Clive Brealey; Elliott B. Grossbard; Muhammad Baluom; David Lau; David Sweeny; Tim Mant; Kelli Craven;
展开▼
作者单位

展开▼
年度 2016
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Effects of CYP3A4 Inhibitors Ketoconazole and Verapamil and the CYP3A4 Inducer Rifampicin on the Pharmacokinetic Parameters of Fostamatinib: Results from In Vitro and Phase I Clinical Studies [J] . Paul Martin, Michael Gillen, David Millson, Drugs in R&D . 2016,第1期

机译：CYP3A4抑制剂酮康唑和维拉帕米以及CYP3A4诱导剂利福平对Fostamatinib药代动力学参数的影响：体外和I期临床研究的结果
2. Evaluation of Ketoconazole and Its Alternative Clinical CYP3A4/5 Inhibitors as Inhibitors of Drug Transporters: The In Vitro Effects of Ketoconazole, Ritonavir, Clarithromycin, and Itraconazole on 13 Clinically-Relevant Drug Transporters [J] . Vermeer Lydia M. M., Isringhausen Caleb D., Ogilvie Brian W., Drug Metabolism and Disposition: The Biological Fate of Chemicals . 2016,第3期

机译：酮康唑及其替代品临床CYP3A4 / 5抑制剂作为药物转运蛋白抑制剂的评价：酮康唑，利托那韦，克拉霉素和伊曲康唑对13种临床相关药物转运蛋白的体外作用
3. Effects of Fostamatinib on the Pharmacokinetics of the CYP2C8 Substrate Pioglitazone: Results From In Vitro and Phase 1 Clinical Studies. [J] . Paul Martin, Michael Gillen, David Millson, Clinical pharmacology in drug development . 2016,第3期

机译：Fostamatinib对CYP2C8底物吡格列酮的药代动力学的影响：体外和1期临床研究的结果。
4. CHARACTERIZATION OF IN VITRO METABOLITES OF TROLEANDOMYCIN, A METABOLISM-DEPENDENT INHIBITOR OF CYP3A4, BY UPLC~(TM) QTOF MASS SPECTROMETRY [C] . Joanna E. Barbara, David Buckley, Phyllis Yerino, American Society for Mass Spectrometry Conference on Mass Spectrometry and Allied Topics . 2009

机译：Troleandomcin体外代谢物，CYPOM3A4的代谢依赖性抑制剂的表征，UPLC〜（TM）质谱法
5. Clinical importance of the drug interaction between statins and CYP3A4 inhibitors [D] . Rowan, Christopher G. 2010

机译：他汀类药物与CYP3A4抑制剂之间药物相互作用的临床重要性
6. Effects of CYP3A4 Inhibitors Ketoconazole and Verapamil and the CYP3A4 Inducer Rifampicin on the Pharmacokinetic Parameters of Fostamatinib: Results from In Vitro and Phase I Clinical Studies [O] . Paul Martin, Michael Gillen, David Millson, 2016

机译：CYP3A4抑制剂酮康唑和维拉帕米以及CYP3A4诱导剂利福平对Fostamatinib药代动力学参数的影响：体外和I期临床研究的结果
7. Evaluation of Ketoconazole and Its Alternative Clinical CYP3A4/5 Inhibitors as Inhibitors of Drug Transporters: The In Vitro Effects of Ketoconazole, Ritonavir, Clarithromycin, and Itraconazole on 13 Clinically-Relevant Drug Transporters [O] . L. M. M. Vermeer, C. D. Isringhausen, B. W. Ogilvie, 2015

机译：评价酮康唑及其替代临床CYP3A4 / 5抑制剂作为药物转运蛋白的抑制剂：酮康唑，Ritonavir，Clarithromycin和Itrogonazole对13个临床相关药转运蛋白的体外影响
8. Phase 2 Report of Preclinical Lethality Studies in Mice, Pharmacokinetic Study in Rats and Dogs, 'In vitro' Protein Binding Study in Rat, Mouse, Dog, and Human Sera, and Toxicity Studies in Dogs and Rats of Chlorsulfaquinoxaline (NSC-339004) [R] . Liao, J. T. , Merriman, T. N. , Collins, W. T. , 1986

机译：小鼠临床前致死率研究的第2阶段报告，大鼠和狗的药代动力学研究，大鼠，小鼠，狗和人类血清中的“体外”蛋白质结合研究，以及氯磺泛喹喔啉（NsC-339004）的狗和大鼠的毒性研究

Effects of CYP3A4 Inhibitors Ketoconazole and Verapamil and the CYP3A4 Inducer Rifampicin on the Pharmacokinetic Parameters of Fostamatinib: Results from In Vitro and Phase I Clinical Studies

著录项

引文网络

相似文献

相关主题

期刊订阅